Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - Ordinary Share
(NQ:
ASND
)
249.55
+0.57 (+0.23%)
Delayed Quote
Updated: 12:31 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma A/S - Ordinary Share
< Previous
1
2
3
4
5
6
7
8
9
Next >
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
↗
March 09, 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...
Via
Talk Markets
These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
↗
March 03, 2024
Ethan Meyers, the research director at Westfield Capital Management, has a knack for identifying promising investments that have proven fruitful, especially for the Harbor Small Cap Growth Fund, where...
Via
Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
↗
February 23, 2024
Via
Benzinga
How Is The Market Feeling About Ascendis Pharma?
↗
February 13, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
↗
February 08, 2024
Via
Benzinga
Earnings Scheduled For February 7, 2024
↗
February 07, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.
Via
Benzinga
Ascendis Pharma's Earnings: A Preview
↗
February 06, 2024
Via
Benzinga
$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today
↗
February 02, 2024
Via
Benzinga
Analyst Expectations for Ascendis Pharma's Future
↗
November 09, 2023
Via
Benzinga
Recap: Ascendis Pharma Q3 Earnings
↗
November 07, 2023
Via
Benzinga
Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
↗
December 19, 2023
Ascendis Pharma A/S (NASDAQ: ASND) released topline results from Phase 3 foresiGHt trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth...
Via
Benzinga
Preview: Ascendis Pharma's Earnings
↗
November 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Ascendis Pharma
↗
October 09, 2023
Via
Benzinga
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
↗
September 28, 2023
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in
Via
Benzinga
The Latest Analyst Ratings for Ascendis Pharma
↗
September 07, 2023
Via
Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 05, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Earnings Preview For Ascendis Pharma
↗
September 04, 2023
Via
Benzinga
Analyst Expectations for Ascendis Pharma's Future
↗
July 24, 2023
Via
Benzinga
Where Ascendis Pharma Stands With Analysts
↗
June 20, 2023
Via
Benzinga
The Latest Analyst Ratings for Ascendis Pharma
↗
June 01, 2023
Via
Benzinga
Earnings Scheduled For September 5, 2023
↗
September 05, 2023
Companies Reporting Before The Bell • Procaps Gr (NASDAQ:PROC) is likely to report earnings for its second quarter.
Via
Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
June 30, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
June 25, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
FDA Rejects Ascendis Pharma's TransCon PTH For Hypoparathyroidism
↗
May 01, 2023
The FDA issued a complete response letter (CRL) for Ascendis Pharma A/S's
Via
Benzinga
Why Shares of Ascendis Pharma Are Climbing Monday
↗
May 01, 2023
A critical response letter from the FDA means hope remains for the company's hyperthyroidism therapy candidate.
Via
The Motley Fool
NASDAQ: ASND Investor Alert: Investigation over Potential Wrongdoing at Ascendis Pharma A/S
↗
June 20, 2023
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- Certain directors of Ascendis Pharma A/S are under investigation over potential breaches of fiduciary duties by certain directors.
Via
SBWire
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
May 01, 2023
Via
Benzinga
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results
↗
May 01, 2023
U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up...
Via
Benzinga
IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session
↗
May 01, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Apollomics, Inc. (NASDAQ: APLM) surged 58.4% to $7.35 in pre-market trading...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
